Archer Materials Limited (AU:AXE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Archer Materials is making strides in advancing its Biochip technology, focusing on improving the accuracy of graphene field effect transistor sensors for blood potassium testing, crucial for chronic kidney disease diagnosis. By refining sensor operations and design, Archer aims to enhance test precision significantly, with recent experiments showing a tenfold improvement in measurement repeatability. This development could revolutionize home diagnostics and patient outcomes by enabling more accurate and accessible chronic kidney disease testing.
For further insights into AU:AXE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue